Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study
about
Insights on common vaccinations in HIV-infection: efficacy and safetyImmunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study.Varicella zoster virus infection.Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?The herpes zoster subunit vaccine.Vaccines for the prevention against the threat of MERS-CoV.Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.Herpes zoster and the search for an effective vaccine.A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.Varicella Zoster Virus and Giant Cell Arteritis.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Vaccines for the elderly: current use and future challenges.Herpes Zoster in the Older Adult.Varicella and herpes zoster vaccine development: lessons learned.The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network.A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profileHerpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity
P2860
Q26770665-235965D6-824C-42F9-A0EC-68BBE6274D5CQ33724403-8C820228-D8E0-489B-AAE2-A7608CDADE41Q36024466-3B257462-567E-4CBC-9CB4-F5BB3DF1A230Q37605555-5260012C-375F-4D42-BDF0-11F3DB2D3F38Q37738789-B3895F5A-2A61-4760-BDE6-36AACB37DD9AQ38638518-548E782B-0600-4D66-AD91-5B8A42B7C24AQ38667215-CD70CBE8-65A6-4DFC-A636-E9ABE2379517Q38728931-1516E23C-453A-4DB7-BE00-9AA7F1DF7732Q38778044-3DCFB2A8-3EDD-444B-B239-A7D961148C7EQ38804622-1FA494BB-B31A-44B8-973C-27819562514BQ38831062-C5A9C96C-BF06-4F98-AB46-CACA49D1FD38Q40234780-1FC50C72-C7FC-4FFF-BE84-FAB6719A8BE2Q42765034-4F27CD38-F3F4-4388-A59B-5A4F759EC52EQ46892547-20B7F31A-27E4-42C5-B521-528A4719F535Q47547388-6663F566-9CE8-4031-9B73-4D02C9F2EBFDQ47597541-2A270416-CA7C-4E7F-BBB5-38A11BB7B444Q47607699-FE65BB37-AEBE-466B-BA6D-AB5363BB440FQ48101757-FE870225-AA4E-46AB-B424-ABE7619A16A5Q48197943-34E3406D-D5D1-47F4-B714-AF5C26D6FF48Q56888201-7BA80A1D-6589-43A0-A2BA-C949CAA22C0AQ58584452-5A01D27C-A506-4C45-9948-E150251B885A
P2860
Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety and immunogenicity of a ...... ized, placebo-controlled study
@ast
Safety and immunogenicity of a ...... ized, placebo-controlled study
@en
Safety and immunogenicity of a ...... ized, placebo-controlled study
@nl
type
label
Safety and immunogenicity of a ...... ized, placebo-controlled study
@ast
Safety and immunogenicity of a ...... ized, placebo-controlled study
@en
Safety and immunogenicity of a ...... ized, placebo-controlled study
@nl
prefLabel
Safety and immunogenicity of a ...... ized, placebo-controlled study
@ast
Safety and immunogenicity of a ...... ized, placebo-controlled study
@en
Safety and immunogenicity of a ...... ized, placebo-controlled study
@nl
P2093
P2860
P356
P1476
Safety and immunogenicity of a ...... ized, placebo-controlled study
@en
P2093
Dirk Schürmann
Elchonon M Berkowitz
Graeme Moyle
Hans-Jürgen Stellbrink
Lidia Oostvogels
Matthias Stoll
Mohamed El Idrissi
Stephen Kegg
Thomas C Heineman
Zoster-015 HZ/su Study Group
P2860
P304
P356
10.1093/INFDIS/JIU606
P407
P577
2014-11-03T00:00:00Z